Fram R - Search Results

1

Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies.

Villalona-Calero MA, Eder JP, Toppmeyer DL, Allen LF, Fram R, Velagapudi R, Myers M, Amato A, Kagen-Hallet K, Razvillas B, Kufe DW, Von Hoff DD, Rowinsky EK. Villalona-Calero MA, et al. Among authors: fram r. J Clin Oncol. 2001 Feb 1;19(3):857-69. doi: 10.1200/JCO.2001.19.3.857. J Clin Oncol. 2001. PMID: 11157040 Clinical Trial.

2

Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.

Villalona-Calero MA, Baker SD, Hammond L, Aylesworth C, Eckhardt SG, Kraynak M, Fram R, Fischkoff S, Velagapudi R, Toppmeyer D, Razvillas B, Jakimowicz K, Von Hoff DD, Rowinsky E. Villalona-Calero MA, et al. Among authors: fram r. J Clin Oncol. 1998 Aug;16(8):2770-9. doi: 10.1200/JCO.1998.16.8.2770. J Clin Oncol. 1998. PMID: 9704730 Clinical Trial.

3

Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.

Cunningham C, Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder JP Jr. Cunningham C, et al. Clin Cancer Res. 2005 Nov 1;11(21):7825-33. doi: 10.1158/1078-0432.CCR-05-0058. Clin Cancer Res. 2005. PMID: 16278405 Clinical Trial.

4

A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion.

Supko JG, Lynch TJ, Clark JW, Fram R, Allen LF, Velagapudi R, Kufe DW, Eder JP Jr. Supko JG, et al. Among authors: fram r. Cancer Chemother Pharmacol. 2000;46(4):319-28. doi: 10.1007/s002800000152. Cancer Chemother Pharmacol. 2000. PMID: 11052630 Clinical Trial.

5

The effect of inhibitors of DNA synthesis on DNA repair.

Fram RJ, Kufe DW. Fram RJ, et al. Nucleic Acids Symp Ser. 1984;(13):95-107. Nucleic Acids Symp Ser. 1984. PMID: 6436789 No abstract available.

6

Effect of 1-beta-D-arabinofuranosyl cytosine and hydroxyurea on the repair of X-ray-induced DNA single-strand breaks in human leukemic blasts.

Fram RJ, Kufe DW. Fram RJ, et al. Biochem Pharmacol. 1985 Jul 15;34(14):2557-60. doi: 10.1016/0006-2952(85)90543-x. Biochem Pharmacol. 1985. PMID: 4015697 No abstract available.

7

Inhibition of DNA excision repair and the repair of X-ray-induced DNA damage by cytosine arabinoside and hydroxyurea.

Fram RJ, Kufe DW. Fram RJ, et al. Pharmacol Ther. 1985;31(3):165-76. doi: 10.1016/0163-7258(85)90021-x. Pharmacol Ther. 1985. PMID: 3939629 No abstract available.

8

DNA strand breaks caused by inhibitors of DNA synthesis: 1-beta-D-arabinofuranosylcytosine and aphidicolin.

Fram RJ, Kufe DW. Fram RJ, et al. Cancer Res. 1982 Oct;42(10):4050-3. Cancer Res. 1982. PMID: 6809309

9

A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.

Ebbinghaus S, Rubin E, Hersh E, Cranmer LD, Bonate PL, Fram RJ, Jekunen A, Weitman S, Hammond LA. Ebbinghaus S, et al. Clin Cancer Res. 2005 Nov 1;11(21):7807-16. doi: 10.1158/1078-0432.CCR-05-0909. Clin Cancer Res. 2005. PMID: 16278403 Clinical Trial.

10

Accumulation of leukemic cell DNA strand breaks with adriamycin and cytosine arabinoside.

Fram RJ, Egan EM, Kufe DW. Fram RJ, et al. Leuk Res. 1983;7(2):243-9. doi: 10.1016/0145-2126(83)90014-0. Leuk Res. 1983. PMID: 6855268

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

82 results

Search Page